PharmSource has released a new report, ADC Market Opportunity for CMOs, addressing the opportunity for Antibody Drug Conjugates and pharma and biopharma industry expectations. The report concludes that CMOs are making significant investments in ADCs but the technology has yet to prove itself in the commercial market. While CMOs can currently profit by serving the need for clinical trial materials, the commercial payoff is still years away.   The report analyzes the ADC pipeline, technology dev...